REG - EKF Diagnostics Hldg - Appointment of CFO

EKF Diagnostics HoldingsAnnouncement

12/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230912:nRSL0831Ma&default-theme=true

RNS Number : 0831M  EKF Diagnostics Holdings PLC  12 September 2023

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

Appointment of CFO

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostic
business, announces the appointment of Stephen ("Steve") Young as Chief
Financial Officer ("CFO") and to the EKF Board, effective immediately. Steve
Young has been working as a consultant at EKF for the last two months
alongside the Group's outgoing CFO to affect an orderly handover.

 

Steve is an experienced Finance Director and CFO and joins the Company from
Trellus Health plc ("Trellus") where he has served as Interim Chief Financial
Officer, in a non-board capacity, since August 2022.

 

Prior to working with Trellus, Steve served as CFO and Company Secretary (a
non-Director role) with Axiom Manufacturing Limited, a contract electronic
manufacturer. Having joined in 2009 when Axiom generated close to £12m in
revenue and was loss making, he supported the restructuring of the business to
over £62m turnover in 2020. Axiom also acquired Greeve Limited in 2016 where
Steve became a Director.

 

In addition to this, Steve has experience with AIM-quoted businesses having
served as CFO at Pure Wafer plc and, before this, BBI Holdings plc ("BBI")
which admitted to AIM in 2004. During Steve's seven-year tenure at BBI he
reported to EKF Executive Chair Julian Baines when he was CEO of BBI. Steve is
a member of the Chartered Institute of Management Accountants (CIMA).

 

Julian Baines, Executive Chair of EKF, commented: "I'm pleased to welcome
Steve Young to the EKF team and to work again with him after doing so at BBI
Holdings plc. Steve is a highly dependable and experienced CFO, with a strong
working knowledge of how AIM companies operate, so I look forward to his
support as we continue to execute against our plans for significant long-term
growth."

 

Additional Disclosures Required under the AIM Rules for Companies

Stephen Michael Young (aged 60) has held the following directorship or
partnerships in the past five years:

 

Current directorships and partnerships:

·    N/A

 

Previous directorships and partnerships held in the past five years:

·    Greeve Limited

 

Stephen currently holds 85,000 ordinary shares in the Company.

 

Save as disclosed above, there is no further information to be disclosed in
respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph
(g) of the AIM Rules for Companies.

 

 EKF Diagnostics Holdings plc                                  www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                                 Tel: +44 (0)29 2071 0570

 Singer Capital Markets (Nominated Adviser & Broker)                                         Tel: +44 (0)20 7496 3000
 Aubrey Powell / George Tzimas / Oliver Platts

 Walbrook PR Limited               Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Lianne Applegarth  Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

·      Point-of-Care analysers in the key areas of Hematology and
Diabetes, as well as Central Laboratory products including clinical chemistry
reagents, analysers and centrifuges

 

·      Life Sciences services provide specialist manufacture of enzymes
and custom products for use in diagnostic, food and industrial applications,
as well as other higher value Contract Manufacturing services

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPUMCBUPWPUG